Virology, pathogenesis, epidemiology and clinical management of HTLV-1 infection. Proceedings of the 30th HTLV European research network (HERN 2023)-Reference-Cited by-同舟云学术

Virology, pathogenesis, epidemiology and clinical management of HTLV-1 infection. Proceedings of the 30th HTLV European research network (HERN 2023)

Published:2024-01-11 Issue:0 Volume:0 Page:
ISSN:2750-6665
Container-title:NeuroImmune Pharmacology and Therapeutics
language:en
Short-container-title:

Author:

de Mendoza Carmen¹,Taylor Graham²,Gessain Antoine³,Thoma-Kress Andrea K.⁴,Bangham Charles²,Vesterbacka Jan⁵,Accolla Roberto⁶,Bazarbachi Ali⁷,van Weyenbergh Johan⁸,Cook Lucy²,Casseb Jorge⁹,Ramos Juan Carlos¹⁰,Rosadas Carolina²,Macchi Beatrice¹¹,Cassar Olivier³,Soriano Vicente¹²

Affiliation:

1. Puerta de Hierro University Hospital , Madrid , Spain

2. Imperial College London , London , UK

3. Institut Pasteur , Université Paris Cité and CNRS , Paris , France

4. Friedrich-Alexander-Universität Erlangen-Nürnberg , Erlangen , Germany

5. Karolinska University Hospital , Stockholm , Sweden

6. University of Insubria , Varese , Italy

7. American University of Beirut , Beirut , Lebanon

8. Rega Institute for Medical Research , KU Leuven , Leuven , Belgium

9. University of Sao Paulo Medical School , Sao Paulo , Brazil

10. University of Miami Miller School of Medicine , Miami , FL , USA

11. University of Rome Tor Vergata , Rome , Italy

12. Health Sciences School , Universidad Internacional de La Rioja (UNIR) , Madrid , Spain

Abstract

Abstract The 30th workshop of the HTLV European Research Network (HERN) was held in Madrid on September 15–16, 2023. Over fifty researchers from Europe and America convened for a two-day conference to update and discuss basic science, epidemiology, clinical management and therapeutics for patients with HTLV-1 infection. Scientific topics addressed included new estimates for HTLV-1 in Europe; impact of antenatal screening on mother-to-child HTLV-1 infections; new insights into the molecular epidemiology of HTLV-1; reports of elite controllers for HTLV-1 infection; role of antiretrovirals as HTLV-1 pre-exposure prophylaxis; and prospects for a HTLV-1 vaccine. The group agreed to submit a formal request to WHO for increasing the global surveillance and awareness of HTLV-1. This viral infection is a potentially life-threatening, neglected condition with neither treatment nor vaccine. At this time, expanding HTLV-1 screening is the most effective way to reduce viral dissemination.

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/nipt-2023-0025/pdf

Reference52 articles.

1. Schierhout, G, McGregor, S, Gessain, A, Einsiedel, L, Martinello, M, Kaldor, J. Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies. Lancet Infect Dis 2020;20:133–43. https://doi.org/10.1016/s1473-3099(19)30402-5.

2. Ramos, JM, de Mendoza, C, Soriano, V, Spanish HTLV Network. HTLV-1 infection and health outcomes. Lancet Infect Dis 2020;20:407–8. https://doi.org/10.1016/s1473-3099(20)30133-x.

3. Legrand, N, McGregor, S, Bull, R, Bajis, S, Valencia, BM, Ronnachit, A, et al.. Clinical and public health implications of HTLV-1 infection. Clin Microbiol Rev 2022;35:e0007821. https://doi.org/10.1128/cmr.00078-21.

4. Gessain, A, Ramassamy, JL, Afonso, P, Cassar, O. Geographic distribution, clinical epidemiology and genetic diversity of the human oncogenic retrovirus HTLV-1 in Africa, the world’s largest endemic area. Front Immunol 2023;14:1043600. https://doi.org/10.3389/fimmu.2023.1043600.

5. de Mendoza, C, Pérez, L, Fernández-Ruiz, M, Pena, MJ, Ramos, JM, Richart, A, et al.. Late presentation of HTLV-1 infection in Spain reflects suboptimal testing strategies. Int J Infect Dis 2022;122:970–5. https://doi.org/10.1016/j.ijid.2022.07.043.